格隆汇11月17日丨亚宝药业(600351.SH)公布，2025年11月14日，公司本次回购计划已实施完毕。公司 通过股份回购专用账户以集中竞价交易方式累计回购股份800万股，占公司总股本的比例为1.14%，回 购的最高成交价为6.65元/股，最低成交价为6.30元/股，回购均价6.52元/股，支付的总金额为人民币 5215.19万元（不含交易费用）。 ...

每经AI快讯，11月17日，亚宝药业(600351.SH)公告称，公司拟将控股子公司太原制药62%的股权出售 给同享科技，交易价格为8718.87万元。交易完成后，同享科技将持有太原制药95%的股权，公司持有 5%，太原制药将不再纳入合并报表。本次交易不构成关联交易或重大资产重组，无需提交股东会审 议。交易对方具备履约能力，但存在不能按协议及时支付股权转让对价的风险。 ...

Core Viewpoint - The company aims to optimize its asset structure and resource allocation, improve asset operation efficiency, and reduce management costs through the transfer of a significant stake in its subsidiary [1] Group 1: Transaction Details - The company signed a share transfer agreement with Tongxiang Technology on November 17, 2025, to transfer 62% of its controlling subsidiary Taiyuan Pharmaceutical for RMB 87.1887 million [1] - After the transaction, Tongxiang Technology will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of this transaction [1]

格隆汇11月17日丨亚宝药业(600351.SH)公布，2025年11月14日，公司本次回购计划已实施完毕。公司 通过股份回购专用账户以集中竞价交易方式累计回购股份800万股，占公司总股本的比例为1.14%，回 购的最高成交价为6.65元/股，最低成交价为6.30元/股，回购均价6.52元/股，支付的总金额为人民币 5215.19万元（不含交易费用）。 ...

Core Viewpoint - The company plans to sell 62.00% of its stake in its subsidiary Taiyuan Pharmaceutical to Shanxi Tongxiang Times Technology Co., Ltd. for a transaction price of 87.1887 million yuan, which is expected to enhance operational efficiency and provide funding support for business expansion [1] Group 1: Transaction Details - The transaction will result in Tongxiang Technology holding 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of the transaction [1] - The transaction does not constitute a related party transaction or a major asset restructuring, and does not require shareholder approval [1] Group 2: Financial Impact - The company estimates that the transaction will increase its total profit by approximately 59 million yuan for the fiscal year 2025 (unaudited) [1] - The final impact amount will be determined based on audited data [1] Group 3: Strategic Benefits - The transaction is expected to improve the company's asset operation efficiency and reduce management costs [1] - It will enhance the company's sustainable operational capabilities and provide financial support for business expansion [1] - The transaction will not affect the company's normal production and operational activities, nor will it harm the interests of the company and all shareholders [1]

证券代码：600351 证券简称：亚宝药业 公告编号：2025-044 亚宝药业集团股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/26，由董事会提议 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 5 11 | 16 | 日~2025 | 年 | 月 | 14 | 日 | | 预计回购金额 | 0.5亿元~1亿元 | | | | | | | | 回购价格上限 | 6.95元/股 | | | | | | | | | √减少注册资本 | | | | | | | | 回购用途 | □用于员工持股计划或股权激励 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 实际回购股数 | 8,000,000股 | | | | | | | | 实际回购股数占总股本比例 ...

本报告依据中国资产评估准则编制 地址:北京市东城区安定门外大街 189 号宝景大厦 7 层 电话:010-51667811 - 传真:010-82253743 - 企业邮箱:grxh@grcpv.com 亚宝药业集团股份有限公司拟转让股权涉及 的亚宝药业太原制药有限公司股东全部权益 价值项目 资产评估报告 国融兴华评报字(2025) 第 010623 号 (共一册,第一册) 北京国融兴华资产评估有限责任公司 2025 年 10 月 23 日 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 1111020056202501776 | | --- | --- | | 合同编号: | 国融兴华(2025) 010314 | | 报告类型: | 法定评估业务资产评估报告 | | 报告文号: | 国融兴华评报字 2025 第010623号 | | 报告名称: | 亚宝药业集团股份有限公司拟转让股权涉及的亚宝 药业太原制药有限公司股东全部权益价值项目资产 评估报告 | | 评估结论: | 140.626,964.11元 | | 评估报告日: | 2025年10月23日 | | 评估机构名称: | 北京国融 ...

亚宝药业太原制药有限公司 2024 年度及 2025 年 1-8 月 审计报告 致同会计师事务所 (特殊普通合伙) l the state 目 录 | 审计报告 | 1-3 | | --- | --- | | 资产负债表 | 1-2 | | 利润表 | 3 | | 现金流量表 | 4 | | 所有者权益变动表 | 5-6 | | 财务报表附注 | 7-39 | 20 12 致富会计师真各所(法院普 FredHx建国 外大街 / -场5层邮编 10000 审计报告 致同审字(2025) 第 110C034312 号 亚宝药业大原制药有限公司董事会: 一、审计意见 我们审计了亚宝药业大原制药有限公司(以下简称太原制药公司)财务 报表,包括 2024年 12月 31 目、2025年 8月 31日的资产负债表,2024年度、 2025 年 1-8 月的利润表、现金流量表、所有者权益变动表以及相关财务报表附 注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编 制,公允反映了太原制药公司 2024年 12月 31 日、2025年 8 月 31 日的财务状 况以及 2024年度、2025年 1-8月的经营 ...

Core Viewpoint - The company plans to transfer 62% of its stake in its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for a transaction price of RMB 87.1887 million [1] Group 1 - After the transaction, Tongxiang Technology will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of the transaction [1]

Core Viewpoint - The company plans to transfer 62% of its stake in its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for a transaction price of RMB 87.1887 million [1] Group 1 - After the transaction, Tongxiang Technology will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of the transaction [1]